Log in
NASDAQ:CLGN

CollPlant Biotechnologies Stock Forecast, Price & News

$6.98
+0.17 (+2.50 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$6.98
Now: $6.98▼
$7.00
50-Day Range
$6.75
MA: $8.14▼
$9.15
52-Week Range
$3.75
Now: $6.98▼
$14.55
Volume10,802 shs
Average Volume16,595 shs
Market Capitalization$39.58 million
P/E RatioN/A
Dividend YieldN/A
Beta0.95
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bio-printing of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. The company's products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. Its products include BioInks for 3D printing of tissues and organs; dermal filler for treating wrinkles; 3D Bioprinted breast implants; VergenixSTR, a soft tissue repair matrix intended for treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.14 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLGN
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.collplant.com
Phone972-73-232-5600
Employees38

Debt

Debt-to-Equity RatioN/A
Current Ratio2.52
Quick Ratio2.19

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E Ratio3.09
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.32 million
Price / Sales17.06
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.72 per share
Price / Book9.69

Profitability

EPS (Most Recent Fiscal Year)($1.29)
Net Income$-11,160,000.00
Net Margins-392.96%
Return on Equity-242.84%
Return on Assets-80.68%

Miscellaneous

Outstanding Shares5,670,000
Market Cap$39.58 million
Next Earnings Date12/4/2020 (Estimated)
OptionableNot Optionable
$6.98
+0.17 (+2.50 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CLGN News and Ratings via Email

Sign-up to receive the latest news and ratings for CLGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











CollPlant Biotechnologies (NASDAQ:CLGN) Frequently Asked Questions

How has CollPlant Biotechnologies' stock been impacted by Coronavirus?

CollPlant Biotechnologies' stock was trading at $10.20 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CLGN shares have decreased by 31.6% and is now trading at $6.98.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of CollPlant Biotechnologies?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CollPlant Biotechnologies in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for CollPlant Biotechnologies.

When is CollPlant Biotechnologies' next earnings date?

CollPlant Biotechnologies is scheduled to release its next quarterly earnings announcement on Friday, December 4th 2020.
View our earnings forecast for CollPlant Biotechnologies.

How were CollPlant Biotechnologies' earnings last quarter?

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) issued its earnings results on Friday, August, 28th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.05. The business had revenue of $0.82 million for the quarter, compared to the consensus estimate of $1.54 million. CollPlant Biotechnologies had a negative return on equity of 242.84% and a negative net margin of 392.96%.
View CollPlant Biotechnologies' earnings history.

What price target have analysts set for CLGN?

1 equities research analysts have issued 1 year price objectives for CollPlant Biotechnologies' shares. Their forecasts range from $13.00 to $13.00. On average, they anticipate CollPlant Biotechnologies' share price to reach $13.00 in the next twelve months. This suggests a possible upside of 86.2% from the stock's current price.
View analysts' price targets for CollPlant Biotechnologies.

Are investors shorting CollPlant Biotechnologies?

CollPlant Biotechnologies saw a decrease in short interest during the month of September. As of September 30th, there was short interest totaling 1,300 shares, a decrease of 31.6% from the September 15th total of 1,900 shares. Based on an average daily trading volume, of 8,700 shares, the short-interest ratio is currently 0.1 days.
View CollPlant Biotechnologies' Short Interest.

Who are some of CollPlant Biotechnologies' key competitors?

Some companies that are related to CollPlant Biotechnologies include Surgalign (SRGA), Milestone Scientific (MLSS), Milestone Scientific (MLSS), ConforMIS (CFMS), Nutriband (NTRB), Histogenics (HSGX), ReWalk Robotics (RWLK), Allied Healthcare Products (AHPI), Myomo (MYO), Myomo (MYO), Predictive Oncology (POAI), Advanced Biomedical Technologies (ABMT), NanoVibronix (NAOV), Bionik Laboratories (BNKL) and Avitar (AVTI).
View all competitors.

What other stocks do shareholders of CollPlant Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CollPlant Biotechnologies investors own include Genocea Biosciences (GNCA), Boingo Wireless (WIFI), Allena Pharmaceuticals (ALNA), Advanced Micro Devices (AMD), Ampio Pharmaceuticals (AMPE), Energy Transfer (ET), HTG Molecular Diagnostics (HTGM), Opko Health (OPK), Ovid Therapeutics (OVID) and Primo Water (PRMW).

Who are CollPlant Biotechnologies' key executives?

CollPlant Biotechnologies' management team includes the following people:
  • Mr. Yehiel Tal, Chief Exec. Officer (Age 68, Pay $495k)
  • Mr. Eran Rotem CPA, Deputy CEO & CFO (Age 52, Pay $311k)
  • Dr. Ilana Belzer, Chief Operations Officer (Age 60, Pay $242k)
  • Prof. Oded Shoseyov, Founder & Chief Scientist (Age 64)

When did CollPlant Biotechnologies IPO?

(CLGN) raised $22 million in an IPO on Friday, December 9th 2016. The company issued 3,500,000 shares at $6.23 per share. Ladenburg Thalmann acted as the underwriter for the IPO and Roth Capital Partners was co-manager.

What is CollPlant Biotechnologies' stock symbol?

CollPlant Biotechnologies trades on the NASDAQ under the ticker symbol "CLGN."

How do I buy shares of CollPlant Biotechnologies?

Shares of CLGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CollPlant Biotechnologies' stock price today?

One share of CLGN stock can currently be purchased for approximately $6.98.

How big of a company is CollPlant Biotechnologies?

CollPlant Biotechnologies has a market capitalization of $39.58 million and generates $2.32 million in revenue each year. The company earns $-11,160,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. CollPlant Biotechnologies employs 38 workers across the globe.

What is CollPlant Biotechnologies' official website?

The official website for CollPlant Biotechnologies is www.collplant.com.

How can I contact CollPlant Biotechnologies?

CollPlant Biotechnologies' mailing address is 4 OPPENHEIMER ST. 11TH FLOOR, REHOVOT L3, 74140. The company can be reached via phone at 972-73-232-5600 or via email at [email protected]

This page was last updated on 10/25/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.